Clinical Trial Update: SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial SCT-I10A plus docetaxel versus placebo in previously treated squamous cell non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SCT-I10A

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Squamous-cell Non-Small-cell Lung Cancer | Phase 3 | Status: TERMINATED